Navigation

Researchers at UCD

researcher

Antoinette Perry

Lecturer/Assistant Professor

School Of Biomolecular & Biomed Science
Conway Institute
Belfield
Dublin 4

Tel: +353 1 7166751
Email: antoinette.perry@ucd.ie

Biography

Dr Antoinette Perry is an Assistant Professor in Cancer Biology at the School of Biomolecular and Biomedical Science at University College Dublin. She is one of a triumvirate of co-directors of the Cancer Biology and Therapeutics laboratory at the UCD Conway Institute (www.cbtlab.ie).

Her research group focuses on translational cancer epigenomics; understanding the role of epigenetic aberrations in the pathogenesis of cancer and harnessing these aberrations to develop prognostic and predictive biomarkers.

Prior to joining UCD in 2015, Dr Perry studied at Trinity College Dublin, where she graduated with a BA in Human Genetics in 2001. She subsequently secured a post-graduate scholarship from the Irish Research Council to fund her PhD in the field of prostate cancer epigenetics, which she carried out at the Institute of Molecular Medicine, Trinity College Dublin. Upon award of her PhD in 2007, Antoinette continued her post-doctoral research in this field at TCD. 

Professional

Honours and Awards

Year: 2009.
Title: Post-doctoral Fellowship
Year: 2015.
Title: Joint Winner, Get Started Technology Venture Programme
Year: 2011.
Title: Young Investigator Award
Year: 2005.
Title: Travel Award
Year: 2002.
Title: Postgraduate Scholarship
Year: 2008.
Title: 1st Prize, Poster Presentations
Year: 2006.
Title: 1st Prize, Oral Presentations
Year: 2010.
Title: 1st Prize, Oral Presentations
Year: 2011.
Title: 1st Prize, ICS Celebration of Research Poster Presentations

Associations

Association: Irish Association of Cancer Research , Function/Role: Treasurer
Association: European Association of Cancer Research, Function/Role: Member
       

Committees

Committee :
Committee : UCD Patient Voice in Cancer Research
Committee : National Kidney Disease Biobank Steering Committee
Committee : Irish Association of Cancer Research
Committee : National Prostate Cancer Research Group

Employment

Employer: Trinity College Dublin
Position: Senior Research Fellow

Education

Year 2001 Institution: Trinity College Dublin
Qualification: BA (Hons) Subject: Human Genetics
Year 2006 Institution: Trinity College Dublin
Qualification: PG DIP Subject: Statistics
Year 2007 Institution: Trinity College Dublin
Qualification: PhD Subject: Cancer Epigenetics
         

Publications

 

Book Chapters

Das S, Moran B, Perry AS. (2018) 'Assessing DNA methylation in Cancer Stem Cells' In: Humana Press (Springer) (eds). Methods in Molecular Biology: Cancer Stem Cells. United States: Humana Press (Springer). [Details]
Perry A.S (2015) 'Therapeutic Applications of the Prostate cancer epigenome' In: Steven Gray (eds). Epigenetic Cancer Therapy. US: Elsevier. [Details]
Perry AS, Baird AM Gray SG. (2015) 'Methods in Molecular Biology: Coeliac Disease' In: Humana Press (eds). Celiac Disease Methods and Protocols. US: Springer. [Details]
 

Peer Reviewed Journals

Bruinsma SM, Roobol MJ, Carroll PR, Pickles T, Moore CM, Gnanapraggasam VJ, Villers A, Rannikko A, Valdagni R, Frydenburg M, Kakehi Y, Filson CP, Bangma CH, The Movember Foundation¿s Global Action Plan Prostate Cancer Active Surveillance (GAP3) consortium. (2017) 'Expert consensus document: Semantics in active surveillance for men with localized prostate cancer - results of a modified Delphi consensus procedure'. Nature Reviews Urology, . [Details]
Bruinsma SM, Zhang L, Bangma C.H, Roobol M.J, Steyerberg E.W, Nieboer D, Van Hemelrijck M, The Movember Foundation¿s Global Action Plan Prostate Cancer Active Surveillance (GAP3) consortium (2017) 'The Movember Foundation's GAP3 cohort: A profile of the largest global prostate cancer active surveillance database to date'. BJU International, . [Details]
Moran B, Silva R, Perry AS, Gallagher W. (2018) 'Epigenetics of Malignant Melanoma'. Seminars in Cancer Biology, . [Details]
Barrabés S, Llop E, Ferrer-Batallé M, Ramírez M, Aleixandre R.N, Perry AS, de Llorens R, Peracaula R. (2017) 'Analysis of urine PSA glycosylation is not indicative of high-risk prostate cancer'. Clinica Chimica Acta, . [Details]
Barrabés S, Farina-Gomez N, Llop E, Puerta A, Diez-Masab JC, Perry AS, de Llorens R, de Frutos M, Peracaula R. (2017) 'Comparative Analysis of Prostate Specific Antigen (PSA) by Two-Dimensional Gel Electrophoresis and Capillary Electrophoresis'. Electrophoresis, 38 (3):408-416. [Details]
Mulvaney EP, Shilling C, Eivers SB, Perry AS, Bjartell A, Kay EW, Watson RW, Kinsella TB (2016) 'Expression of the Alpha and Beta Isoforms of the Thromboxane Prostanoid Receptor (TP) in Human Prostate Cancer ¿ Clinical Significance and Diagnostic Potential'. Oncotarget, . [Details]
Foley, R.W., Gorman, L.V., Sharifi, N., Lundon, D.J., Murphy, K., Moore, H., Tuzova, A., Perry, A., Murphy, T.B. and Watson, R.W.G. (2016) 'Improving Multivariable Prostate Cancer Risk Assessment Using The Prostate Health Index'. BJU International, 117 (3):409-417. [DOI] [Details]
Perry AS, Baird AM;Gray SG (2015) 'Epigenetic Methodologies for the Study of Celiac Disease'. Methods in molecular biology (Clifton, N.J.), 1326 :131-158. [DOI] [Details]
Bolton EM, Tuzova AV;Walsh AL;Lynch T;Perry AS (2014) 'Noncoding RNAs in prostate cancer: the long and the short of it'. Clinical Cancer Research, 20 (1):35-43. [DOI] [Details]
Walsh AL, Tuzova AV;Bolton EM;Lynch TH;Perry AS (2014) 'Long noncoding RNAs and prostate carcinogenesis: the missing 'linc'?'. Trends in Molecular Medicine, 20 (8):428-436. [DOI] [Details]
Vajda A, Marignol L;Barrett C;Madden SF;Lynch TH;Hollywood D;Perry AS (2013) 'Gene expression analysis in prostate cancer: the importance of the endogenous control'. Prostate, 73 (4):382-390. [DOI] [Details]
O'Rourke CJ, Murphy TM;Hollywood D;Perry AS (2013) 'Mining methylome databases'. Trends in genetics : TIG, 29 (2):63-65. [DOI] [Details]
O'Rourke CJ, Knabben V;Bolton E;Moran D;Lynch T;Hollywood D;Perry AS (2013) 'Manipulating the epigenome for the treatment of urological malignancies'. Pharmacology & therapeutics, 138 (2):185-196. [DOI] [Details]
Perry AS, O'Hurley G;Raheem OA;Brennan K;Wong S;O'Grady A;Kennedy AM;Marignol L;Murphy TM;Sullivan L;Barrett C;Loftus B;Thornhill J;Hewitt SM;Lawler M;Kay E;Lynch T;Hollywood D (2013) 'Gene expression and epigenetic discovery screen reveal methylation of SFRP2 in prostate cancer'. International Journal of Cancer, 132 (8):1771-1780. [DOI] [Details]
O'Kelly F, Marignol L;Meunier A;Lynch TH;Perry AS;Hollywood D (2012) 'MicroRNAs as putative mediators of treatment response in prostate cancer'. Nature reviews. Urology, 9 (7):397-407. [DOI] [Details]
Gray SG, Baird AM;O'Kelly F;Nikolaidis G;Almgren M;Meunier A;Dockry E;Hollywood D;Ekstr¿¿m TJ;Perry AS;O'Byrne KJ (2012) 'Gemcitabine reactivates epigenetically silenced genes and functions as a DNA methyltransferase inhibitor'. International Journal of Molecular Medicine, 30 (6):1505-1511. [DOI] [Details]
Sullivan L, Murphy TM;Barrett C;Loftus B;Thornhill J;Lawler M;Hollywood D;Lynch T;Perry AS (2012) 'IGFBP7 promoter methylation and gene expression analysis in prostate cancer'. Urology, 188 (4):1354-1360. [DOI] [Details]
Murphy TM, Sullivan L, Lane C, O'Connor L, Barrett C, Hollywood D, Lynch T, Lawler M, Perry AS; (2011) 'In silico analysis and DHPLC screening strategy identifies novel apoptotic gene targets of aberrant promoter hypermethylation in prostate cancer'. Prostate, 71 (1):1-17. [DOI] [Details]
Forde JC, Perry AS;Brennan K;Martin LM;Lawler MP;Lynch TH;Hollywood D;Marignol L (2012) 'Docetaxel maintains its cytotoxic activity under hypoxic conditions in prostate cancer cells'. Urologic oncology, 30 (6):912-919. [DOI] [Details]
O'Hurley G, Perry AS;O'Grady A;Loftus B;Smyth P;O'Leary JJ;Sheils O;Fitzpatrick JM;Hewitt SM;Lawler M;Kay EW (2011) 'The role of secreted frizzled-related protein 2 expression in prostate cancer'. Histopathology, 59 (6):1240-1248. [DOI] [Details]
Prencipe M, McGoldrick A, Perry AS, O'Grady A, Phelan S, McGrogan B, Fitzpatrick P, Watson JA, Furlong F, Brennan DJ, Lawler M, Kay E, McCann A; (2010) 'MAD2 downregulation in hypoxia is independent of promoter hypermethylation'. Cell Cycle, 9 (14):2856-2865. [Details]
Magee AM, Aspinall S;Rice DW;Cusack BP;S¿¿mon M;Perry AS;Stefanovi¿¿ S;Milbourne D;Barth S;Palmer JD;Gray JC;Kavanagh TA;Wolfe KH (2010) 'Localized hypermutation and associated gene losses in legume chloroplast genomes'. Genome Research, 20 (12):1700-1710. [DOI] [Details]
Perry AS, Watson RW, Lawler M, Hollywood D (2010) 'The epigenome as a therapeutic target in prostate cancer'. Nature Reviews Urology, 7 (12):668-680. [DOI] [Details]
Foley R, Marignol L;Thomas AZ;Cullen IM;Perry AS;Tewari P;O'Grady A;Kay E;Dunne B;Loftus B;Watson WR;Fitzpatrick JM;Woodson K;Lehman T;Hollywood D;Lynch TH;Lawler M (2009) 'The HIF-1alpha C1772T polymorphism may be associated with susceptibility to clinically localised prostate cancer but not with elevated expression of hypoxic biomarkers'. Cancer biology & therapy, 8 (2):118-124. [Details]
Murphy TM, Perry AS, Lawler M; (2008) 'The emergence of DNA methylation as a key modulator of aberrant cell death in prostate cancer'. Journal of Cancer, 15 (1):11-25. [DOI] [Details]
Perry AS, Liyanage H;Lawler M;Woodson K (2007) 'Discovery of DNA hypermethylation using a DHPLC screening strategy'. Epigenetics, 2 (1):43-49. [Details]
Perry AS, Loftus B;Moroose R;Lynch TH;Hollywood D;Watson RW;Woodson K;Lawler M (2007) 'In silico mining identifies IGFBP3 as a novel target of methylation in prostate cancer'. British Journal of Cancer, 96 (10):1587-1594. [DOI] [Details]
Perry AS, Foley R;Woodson K;Lawler M (2006) 'The emerging roles of DNA methylation in the clinical management of prostate cancer'. Endocrine-Related Cancer, 13 (2):357-377. [DOI] [Details]
Perry AS, Brennan S;Murphy DJ;Kavanagh TA;Wolfe KH (2002) 'Evolutionary re-organisation of a large operon in adzuki bean chloroplast DNA caused by inverted repeat movement'. DNA research : an international journal for rapid publication of reports on genes and genomes, 9 (5):157-162. [Details]
Perry AS, Wolfe KH (2002) 'Nucleotide substitution rates in legume chloroplast DNA depend on the presence of the inverted repeat'. Journal of Molecular Evolution, 55 (5):501-508. [DOI] [Details]

Other Journals

Foley, R.W., Murphy, K., Lundon, D., Perry, A., Power, R., Durkan, G., O'Brien, F., O'Malley, K., Galvin, D., Murphy, T.B. and Watson, R.W. (2015) 'Prostate volume estimation can significantly improve prostate cancer diagnosis' BJU International 116 (Supplement 2) :20-20. [DOI] [Details]
Foley, R., Murphy, K., Lundon, D., Power, R., Perry, A., Murphy, T.B., Galvin, D., Watson, R.W. (2015) 'The creation, internal validation and external validation of a novel clinical prediction model for the early diagnosis of prostate cancer' International Journal of Surgery 23 (Supplement 1) :S120-S121. [DOI] [Details]
Foley, R., Gorman, L., Lundon, D., Sharifi, N., Murphy, K., Tuzova, A., Perry, A., Murphy, T.B. and Watson, R.W. (2015) 'Analysis of pro [-2] PSA: A novel biomarker that significantly improves the detection of prostate cancer' International Journal of Surgery 23 (Supplement 1) :S15-S15. [DOI] [Details]

Conference Publications

Perry, A, Loftus, B, Moroose, R, Lynch, T, Hollywood, D, Watson, RWG, Woodson, K, Lawler, M, (2007) Promoter hypermethylation of IGFBP3 is an early event in prostate carcinogenesis European Association of Urology , pp.191-191 [Details]
D'Arcy, F., Foley, R., Perry, A., Marignol, L., Lawler, M., Gaffney, E., Watson, R. G. W., Fitzpatrick, J. M., Lynch, T. H., ; (2008) No evidence of XMRV in irish prostate cancer patients with the R462q mutation European Association of Urology , pp.271-271 [Details]
                                         

Abstract

Perry A, Loftus R, Moroose R, Lynch T, Hollywood D, Watson RW, Woodson K, Lawler M. (2007) Promoter hypermethylation of IGFBP3 is an early event in prostate carcinogenesis. Abstract [Details]
Foley R. Murphy K, Lundon D, Perry A, Power R, Durken GC, O'Brien F, O'Malley K, Galvin DJ, Murphy TB, Watson RW (2015) An Irish Prostate Cancer Risk Calculator. Abstract [Details]
Foley R, Gorman L, Lundon D, Shafifi N, Murphy K, Tuzova A, Perry A, Murphy TB, Watson RW (2015) Analysis of pro[-2] PSA: A novel biomarker that significantly improves the detection of prostate cancer. Abstract [Details]
D'Arcy, F,Foley, R,Perry, A,Marignol, L,Gaffney, E,Dunne, B,Lawler, MP,Watson, RWG,Fitzpatrick, JM,Lynch, TH (2007) RNASEL and its role in Irish prostate cancer patients. Abstract [Details]
D'Arcy, F,Foley, R,Perry, A,Marignol, L,Lawler, M,Gaffney, E,Watson, RGW,Fitzpatrick, JM,Lynch, TH (2008) No evidence of XMRV in irish prostate cancer patients with the R462q mutation. Abstract [Details]
                                                                 

Comment

Perry AS (2012) Prostate cancer epigenomics. Comment [DOI] [Details]
                       

Research

Research Interests

My major research interests are focused on translational prostate cancer epigenetics; understanding the role of epigenomic aberrations in the pathogenesis of prostate cancer and harnessing these aberrations to develop prognostic and predictive biomarkers. I have a particular interest in studying DNA methylation changes in the prostate gland and in "liquid biopsies" that can act as surrogates for non-invasive tumour detection and monitoring. My research has highlighted the importance of epigenetic dysregulation of the Wnt and IGF axis in prostate cancer, and has identified a number of potential biomarkers for aggressive prostate cancer. 

My research has been funded by

Research Projects

Sponsor : Health Research Board (HRB)
Title : Building a risk calculator to inform prostate cancer diagnosis
Start Date / End Date : 09-DEC-16 / 31-JUL-19
Sponsor : Science Foundation Ireland (SFI)
Title : epiCaPture: A non-invasive urine test for early detection of High-Risk Prostate Cancer
Start Date / End Date : 01-OCT-15 / 09-OCT-16
Sponsor : Movember Group Pty Ltd
Title : MOVEMBER GAP1 Urine Project
Start Date / End Date : 17-NOV-15 / 29-FEB-16
Sponsor : University College Dublin (UCD)
Title : Investigation into chemopreventative properties of seaweeds: potential for Irish nutraceutical industry
Start Date / End Date : 01-APR-16 / 30-SEP-17
Sponsor : University College Dublin (UCD)
Title : methCaP: DNA methylation beyond the gene promoter: deep analysis into nonconventional roles in prostate tumorigenesis
Start Date / End Date : 01-APR-16 / 31-MAR-18
Sponsor : Trinity College Dublin (TCD)
Title : Perry_Prostate_Research_account
Start Date / End Date : 13-APR-16 / 15-JUL-16
Sponsor : Irish Cancer Society (ICS)
Title : iPROSPECT
Start Date / End Date : 12-SEP-15 / 31-MAR-17
Sponsor : University College Dublin (UCD)
Title : Synergising epigenetics and biosensors to advance point of care cancer diagnostics
Start Date / End Date : 01-AUG-16 / 31-JAN-18
Sponsor : University College Dublin (UCD)
Title : Evaluation of the robustness of a new urine assay to detect prostate cancer
Start Date / End Date : 24-MAY-16 / 30-JUN-18
Sponsor : Enterprise Ireland (EI)
Title : epiCaPture: a non-invasie urine test for early detection of high-risk prostate cancer
Start Date / End Date : 21-SEP-16 / 21-DEC-16
Sponsor : University College Dublin (UCD)
Title : OBRSS Research Support Scheme
Start Date / End Date : 01-NOV-16 / 31-OCT-19
Sponsor : Science Foundation Ireland (SFI)
Title : epiCaPture: A non-invasive urine test for early detection of High-Risk Prostate Cancer
Start Date / End Date : 01-JAN-17 / 31-DEC-17
Sponsor : Enterprise Ireland (EI)
Randox Teoranta
Title : Validation and Risk Calculator Integration of Novel Biomarkers for Detection of Prostate Cancer
Start Date / End Date : 19-JAN-17 / 19-JUL-18
Sponsor : Irish Cancer Society (ICS)
Title : PROVE - PRostate and OVarian Epigenetics: investigating therapeutic resistance via cfDNA
Start Date / End Date : 01-JAN-18 / 01-JAN-22
Sponsor : Dept. of Cultural Affairs, Libya
Title : Chemoprevention and Chemotherapeutics
Start Date / End Date : 15-MAY-17 / 14-MAY-18
Sponsor : Trinity College Dublin (TCD)
Title : MSc Molecular Medicine
Start Date / End Date : 01-MAY-17 / 30-APR-18
Sponsor : Irish Research Council (IRC)
Title : Investigating chemopreventative and chemotherapeutic applications of terrestrial and marine plants
Start Date / End Date : 01-JAN-18 / 31-DEC-21
Sponsor : Irish Cancer Society (ICS)
Title : Deciphering Epigenetic Regulators of Enhancers in Agrressive Prostate Cancer
Start Date / End Date : 01-OCT-15 / 30-APR-20
Sponsor : Royal Irish Academy (RIA)
Title : RIA / RS International Cost Share Agreement
Start Date / End Date : 09-OCT-15 / 28-FEB-17

Recent Postgraduates


Alexandra Tuzova - MSc - 2015
Therese Murphy - PhD - 2011
Colm O'Rourke - PhD 2014 

Current Postgraduate Students

Alexandra Tuzova, Doctor of Philosophy (PhD)   -   Thesis Co-Supervisor
Eve O'Reilly, Doctor of Philosophy (PhD)   -   Thesis Supervisor
Karima Khalifa, Doctor of Philosophy (PhD)   -   Thesis Supervisor
Romina Silva, Doctor of Philosophy (PhD)   -   Thesis Co-Supervisor

Teaching

 

Modules Coordinated

201700   BIOC40110     Biochemistry: Biomedical Diagnostics
201700   PHAR30070     Pharmacology: Endocrine Diseases
201700   BMOL40050     Biomolecular & Biomed Science: Adv Pharmacology of Cancer
       

Collaborators

Internal Collaborators

Professor Liam Gallagher, SBBS
Professor Donal Brennan, Medicine
Professor Gil Lee, Chemistry (UCD Interdisciplinary Award 2016)
Professor Bill Watson, Medicine 

External Collaborators

Professor John Greally, Einstein College of Medicine, NY, USA
Professor Marty Sanda, Emory, GA, USA
Dr Jeremy Clark and Professor Colin Cooper, University of East Anglia, UK 
Dr Ronan Sulpice and Professor Michael Guiry, NUIG, Ireland  

Greenlight Medicines, Ireland
Randox Teoranta, Ireland